Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$3.31 - $18.51 $51,831 - $289,848
-15,659 Reduced 48.11%
16,889 $71,000
Q1 2024

May 10, 2024

BUY
$9.77 - $21.47 $214,627 - $471,652
21,968 Added 207.64%
32,548 $479,000
Q4 2023

Feb 14, 2024

BUY
$4.48 - $10.11 $28,703 - $64,774
6,407 Added 153.53%
10,580 $101,000
Q3 2023

Nov 09, 2023

SELL
$4.48 - $6.19 $117,824 - $162,797
-26,300 Reduced 86.31%
4,173 $19,000
Q2 2023

Aug 09, 2023

SELL
$4.62 - $7.54 $8,523 - $13,911
-1,845 Reduced 5.71%
30,473 $163,000
Q1 2023

May 12, 2023

BUY
$4.82 - $7.24 $155,772 - $233,982
32,318 New
32,318 $231,000
Q2 2022

Aug 11, 2022

BUY
$2.25 - $9.99 $207 - $919
92 New
92 $0
Q4 2021

Feb 11, 2022

SELL
$15.91 - $21.88 $279,156 - $383,906
-17,546 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$19.74 - $28.7 $189,188 - $275,060
9,584 Added 120.37%
17,546 $367,000
Q2 2021

Aug 10, 2021

BUY
$20.49 - $35.63 $140,315 - $243,994
6,848 Added 614.72%
7,962 $214,000
Q1 2021

May 12, 2021

BUY
$18.99 - $33.2 $21,154 - $36,984
1,114 New
1,114 $35,000
Q2 2020

Aug 13, 2020

SELL
$5.2 - $29.12 $73,153 - $409,660
-14,068 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$4.28 - $12.11 $60,211 - $170,363
14,068 New
14,068 $82,000
Q3 2019

Nov 12, 2019

SELL
$12.44 - $17.48 $126,614 - $177,911
-10,178 Closed
0 $0
Q2 2019

Aug 09, 2019

SELL
$14.51 - $19.71 $274,166 - $372,420
-18,895 Reduced 64.99%
10,178 $173,000
Q1 2019

May 13, 2019

BUY
$11.11 - $25.6 $318,412 - $733,696
28,660 Added 6939.47%
29,073 $523,000
Q4 2018

Feb 06, 2019

BUY
$11.75 - $21.42 $4,852 - $8,846
413 New
413 $5,000
Q1 2018

May 11, 2018

SELL
$18.89 - $32.46 $22,913 - $39,373
-1,213 Closed
0 $0
Q4 2017

Feb 09, 2018

SELL
$16.19 - $20.3 $23,281 - $29,191
-1,438 Reduced 54.24%
1,213 $23,000
Q3 2017

Nov 15, 2017

SELL
$15.52 - $18.94 $20,936 - $25,550
-1,349 Reduced 33.73%
2,651 $49,000
Q2 2017

Aug 14, 2017

BUY
N/A
4,000
4,000 $70,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $200M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.